Pfizer signs deal to let generic drug companies make its COVID-19 antiviral pill – CBC

Arrangement would make the pill available to many poor and middle-income countries

Nov 16, 2021

Pfizer Inc. has signed a deal with a UN-backed group to allow other manufacturers to make its experimental COVID-19 antiviral pill, a move that could make the treatment available to more than half of the world’s population.

In a statement issued Tuesday, Pfizer said it would grant a licence for the antiviral pill to the Geneva-based Medicines Patent Pool, which would let generic drug companies produce the pill for use in 95 countries, making up about 53 per cent of the world’s population.

The deal excludes some large countries that have suffered devastating coronavirus outbreaks. For example, while a Brazilian drug company could get a licence to make the pill for export to other countries, the medicine could not be made generically for use in Brazil.

Still, health officials said the fact that the deal was struck even before Pfizer’s pill has been authorized anywhere could help to end the pandemic quicker.

Read more: https://www.cbc.ca/news/health/pfizer-covid-19-antiviral-generic-manufacturers-agreement-1.6250458

NationTalk Partners & Sponsors Learn More